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Summary 
A new neutrophil-activating peptide, termed ENA-78, was identified in the conditioned media 
of stimulated human type II epithelial cell line A549.  In response to stimulation with either 
interleukin 13 (II-13) or tumor necrosis factor c~ (TNF-o0, ENA-78 was produced and secreted 
concomitantly with II.-8, GtkOcz, and GRO3,. ENA-78 consists of 78 amino acids (AGPAAA- 
VLILELRCVCLQTTQGVHPKMISNLQVFAIGPQCSKVEVVASLKNGKEICLDPEAPFLKK- 
VIQKILDGGNKEN)  and has a molecular weight of 8,357.  It has four cysteines positioned 
identically to those of Ib8 and analogues,  and thus belongs to the CXC family of peptides. 
ENA-78 is related to neutrophil-activating peptide 2 (NAP-2) and GtkOo~ (sequence identity, 
53% and 52%, respectively) and II,8 (22% identity). Like NAP-2 and GILO~ ENA-78 stimulates 
neutrophils, inducing chemotaxis, a rise  in intracellular free calcium and exocytosis.  Cross- 
desensitization experiments indicate that ENA-78 acts through the same type of receptors as 
Ib8,  NAP-2, and GtLOo~. 
N 
'eutrophil activation and chemotaxis have recently ac- 
quired increased attention through the discovery of the 
potent neutrophil activating peptide 1/IL-8  (1-4).  Subse- 
quently, two structural homologues with similar biological 
activities  on human neutrophils were detected, neutrophil- 
activating peptide 2 (NAP-2), 1 which is formed by proteo- 
lyric processing from platelet basic protein or connective-tissue 
activating peptide III released from platelet cx granules (5, 
6), and GROcx, which was originally described as a mitogen 
for human melanoma cells (7) and was subsequently shown 
to activate neutrophils (8, 9). I1,8, NAP-2, and GROcx be- 
long to a family of peptides with a molecular mass of 8-10 
kD, containing four conserved cysteine residues, the first two 
spaced by one amino acid (CXC).  Two other members of 
this family are platelet factor 4 (PF-4) and IFN-~/-inducible 
peptide 10 (3'IP-10) (10, 11). 
Whereas the formation of NAP-2 is probably limited to 
the vascular system, IL-8 and GROol were shown to be secreted 
by a wide variety of cells (for review, see reference 12). This 
and the demonstration of their in vivo chemotactic activity 
1  Abbreviations used in this paper: DEPC,  diethylpyrocarbonate;  "piP-10, 
IFN-3,-inducible  peptide  10; MCP-1, monocyte chemotactic  protein  1; 
NAP-2, neutrophil-activating  peptide  2; PF-4,  plateht  factor  4; TFA, 
trifluoroacetic  acid. 
strongly support their involvement in a number of inflam- 
matory processes through the triggering of neutrophil infiltra- 
tion and activation. 
Neutrophil infiltration into the alveolar space is promi- 
nent in a variety of acute and chronic pulmonary inflamma- 
tory disorders (13-15). Alveolar macrophages (16, 17), as well 
as lung epithelial cells (18) and fibroblasts  (19), have been 
shown to produce II.-8 in response to stimulation. Ib8 is also 
released by endothelial cells, which, like macrophages, respond 
to LPS in addition to IL-1 and TNF-ol (20). Lung fibroblasts 
were shown to produce GROol in addition to IL-8 when 
stimulated with inflammatory cytokines (19). Since the pul- 
monary alveolus is in direct contact with the external envi- 
ronment, the alveolar macrophage might be the primary target 
of exogenous stimuli, such as viruses or bacterial products, 
which induce the expression of proinflammatory cytokines 
such as I1,1 and TNF-ol. 
Type II alveolar cells appear to have a prominent role in 
the generation of neutrophil attractants. Here we describe 
the isolation and complete primary structure of a novel neu- 
trophil activating peptide (ENA-78)  from the human type 
II epithelial cell line A549. ENA-78 has the same overall struc- 
ture as the other members of the CXC family of peptides 
and matches IbS, NAP-2, and GROol in terms of biological 
activity. 
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Reagents.  Human rlL-l~ (30 U/ng), human rTNF-o~  (22 U/ng), 
and human rlL-8 (34) were kindly provided by Upjohn (Kalamazoo, 
MI), Genentech (San Francisco, CA) and Sandoz (Vienna, Aus- 
tria), respectively.  NAP-2 was purified as described previously (5). 
Synthetic oligonucleotides were prepared on a DNA Synthesizer 
(391; Applied Biosystems, Inc., Foster City, CA) and desalted on 
NAP 10 columns (Pharmacia Fine Chemicals, Piscataway, NJ). 
Cells.  A549  pulmonary epithelial cells (American Type Cul- 
ture Collection, Rockville, MD) were grown to confluency  in 225- 
cm  ~  culture flasks (Costar, Cambridge, MA) with complete RPMI 
1640, plus 10% FCS. Confluent monolayers were washed free of 
FCS with RPMI and stimulated for 24 h with 1 #g/ml LPS, 20 
ng/ml TNF-~x, or 10 ng/ml IL-I~ (300 ml KPMI per flask). Cell- 
free supernatants were then collected and stored at  -75~  Total 
cellular RNA was extracted  from the monolayers  as described  below. 
Human neutrophils were isolated and used as described previously 
(21). 
Isolation ofPoly(A) RNA.  Total  cellular RNA from A549 cells 
was isolated using a modification of the methods of Chirgwin et 
al. (22) and Jonas et al. (23). Briefly,  A549 monolayers  were scraped 
into a solution of 25 mM Tris/HC1, pH 8.0, containing 4.2 M 
guanidine isothiocyanate,  0.5% sarcosyl,  and 100 mM 2-ME. After 
homogenization,  an equal volume of 100 mM Tris/HC1, pH 8.0, 
containing 10 mM EDTA and 1% SDS was added, and the mix- 
ture was extracted twice with chloroform-phenol and chloroform- 
isoamyl alcohol. The RNA was precipitated with isopropyl  alcohol, 
washed with 80% ethanol in diethylpyrocarbonate-treated water 
(DEPC-water),  and the pellet dissolved in DEPC-water. Poly(A) 
RNA was then isolated by two passages on an oligo(dT)-cellulose 
column. 
Preparation ofcDNA.  First-strand synthesis was carried out in 
a total volume of 40/zl in the presence of 0.5 ~g random hexamer 
primer or 4.2/xg ENA-78 antisense primer (see Fig. 5 a), 2 k~g 
of poly(A) RNA, 40 U RNAsin (Promega Biotec, Madison, WI), 
1 mM  each of dNTPs,  400  U  of MMLV reverse transcriptase 
(Bethesda Research Laboratories, Bethesda, MD), and 8 #1 of 5 x 
reverse transcriptase buffer (250 mM Tris/HC1, pH 8.3, 375 mM 
KC1, 15 mM MgC12, 50 mM DTT). This reaction mixture was 
incubated for 2 h at 37~ 
PCK reactions were carried out on the first-strand cDNA in 
50/A containing 4 #1 of 10x PCK buffer (500 mM KC1, 100 mM 
Tris/HC1, pH 8.3, 15 mM MgC12, and 0.01% gelatin), 10 #I first- 
strand reaction, 3 #g ofENA-78 antisense primer, 4.5 #g of  ENA- 
78 sense primer (see Fig. 5 a), and 1 U Taq polymerase (Perkin- 
Elmer Cetus, Norwalk, CT). The PCR was run for 35 cycles  (40 s 
at 95~  90 s at 55~  90 s at 72~  in a thermocycler (PHC-2; 
Techne Inc., Princeton, NJ). The final product was extracted three 
times with phenol/chloroform and four times with ether. The DNA 
was then precipitated with 0.3 M Na-acetate and 2.5 vol of  ethanol. 
Cloning Procedures.  The PCR product was resuspended in so- 
dium chloride, Tris/HCL, EDTA (STE), restricted with EcoRI and 
BamHI,  and separated on a 5% NuSieve agarose gel in 40 mM 
"iris, 20 mM acetate, pH 8.0, 2 mM EDTA. DNA was visualized 
by staining with ethidium bromide, bands were cut out, electroe- 
luted (Biotrap; Schleicher  & Schuell, Inc., Keene, NH), and ligated 
into plasmid pTZ18K (Pharmacia, Duebendorf, Switzerland). The 
construct was then transfected into Escherichia coli HB101 by elec- 
troporation (Gene Pulser; Bio-Rad Laboratories, Richmond, CA) 
at 2.5 kV, 25 #F, 400 Ohms.  A number of positive clones were 
analyzed for their inserted cDNA by DNA sequencing with Se- 
quenase (United  States Biochemical Corp.,  Cleveland, OH). 
Isolation of  Neutrophil-activating Peptides.  Serum-free culture su- 
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pernatants (450 ml) from the A549 pulmonary epithelial cells were 
diluted with one volume of loading buffer (20 mM KHPO4, pH 
7.5, 20 mM NaC1, 5% glycerol), and loaded onto a 12-ml phos- 
phocellulose  column (P11; Whatman Inc., Clifton, NJ) equilibrated 
with loading buffer. The column was washed with the same buffer 
containing 200 mM NaC1 and then eluted with buffer containing 
1 M NaC1 (24 ml/min). Active fractions were pooled and further 
purified by repeated runs on a wide-pore analytical reversed-phase 
cyanopropyl column (4.6  x  250 mm; Baker Research Products, 
PhiUipsburg, NJ), which was eluted at 0.5 ml/min with a linear 
gradient of 0-50% acetonitrile in 0.1% trifluoroacetic acid (TFA) 
(0.83% increment per rain). Active fractions were pooled, dried 
in a Speed-Vac  centrifuge, resuspended in 0.1% TFA, and further 
purified on a C4 reversed-phase column (4.6  x  250 ram; Baker 
Research Products), which was eluted at 0.5 ml/min with a linear 
gradient of 0-63% acetonitrile in 0.1% TFA (0.83% increment 
per min). Active fractions were rerun on a narrow-bore C4 column 
(2.1 x  100 ram; 7/~m, Brownlee/Applied Biosystems, Inc.) which 
was eluted at 0.3 ml/min with a linear gradient of 0-63% acetoni- 
trile in 0.1% TFA (0.84%  increment per min). 
Amino Acid Sequence Analysis,  This was performed with a gas 
phase sequencer (477A; Applied Biosystems, Inc.) (5). Cleavage 
at the Asp-Pro bond of purified, unmodified  ENA-78 was performed 
in 75% (vol/vol) formic acid at 37~  for 60 h. The digestion mix- 
ture was then diluted four times with 0.1% TFA and loaded directly 
onto a narrow-bore reversed-phase  C4 column as described above. 
Neutrophil Activation.  Established methods were used to assess 
elastase release  (21) and cytosolic  free calcium changes (24) in human 
neutrophils. 
Neutrophil migration was determined in multiwell chemotaxis 
chambers (Neuro Probe,  Cabin John,  MD)  (25). Dilutions  of 
chemoattractants were loaded into the bottom wells in triplicates 
in prewarmed (37~  MEM supplemented with 0.2% BSA, and 
the chambers (also prewarmed) were assembled with a 5-#m pore 
diameter polyvinylpyrrolidone-free  polycarbonate membrane (Nu- 
cleopore; Neuro Probe, Cabin John, MD). Freshly isolated human 
neutrophils were placed into the upper wells (25,000 cells per well 
in 50 #1 of MEM supplemented with 0.2% BSA) and chambers 
incubated at 37~  for 1 h in humidified air with 5% COs.  The 
polycarbonate filters were then removed and the cells on the upper 
surface were wiped off. After air drying,  the filters were stained 
with DADE Diff-Quik (Merz & Dade AG, Dfidingen, Switzer- 
land). Migrated cells were counted microscopically at 1,000 mag- 
nification in five randomly chosen fields per well (0.03 mm2/field 
of 3.17 mm  2 total area per well). Each point in Fig. 6 represents 
the average of three independent experiments (15 fields per ex- 
periment). 
Results 
ENA-78 and Other Neutrophil-acfivating Peptides.  As shown 
in Fig. 1, stimulation of pulmonary epithelial cells by TNF-ot 
or IL-lfl led to production and release of substantial amounts 
of neutrophil-activating Peptides.  On  HPLC,  the activity 
eluted into a broad peak with a retention time extending be- 
tween 35 and 45 min, and a sharper peak eluting after 49 
min. Only minor activity was recovered in the supernatant 
of unstimulated or LPS-stimulated cells. 
For purification and sequence analysis, liter quantities of 
conditioned medium from IL-lfl- and TNF-a-treated cultures 
were fractionated. HPLC on a CN-propyl column yielded 
three well-resolved peaks of activity (P1-P3) with mean reten- 
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Figure 1.  Recmed-phase  ~n'LC 
of neutrophil-activating peptides 
released by A549 cells. The cells 
were cultured  for 24 h in medium 
without  addition (a)  or in the 
presence of I/zg/ml LPS (b), 10 
ng/ml  IL-13 (c), or  20  ng/ml 
TNF-ol (d), The culture superna- 
rants were  collected  and fraction- 
ated by cation-exchange  chroma- 
tography  on  phosphocellulose, 
followed  by reversed-phase  HPI.C 
on  a CN-propyl column. The 
graphs show neutrophil-stimu- 
lating  activity (elastase release 
from cytochalasin  B-treated  human 
neutrophils) versus elution time 
on HPLC. 
tion times of 29,  35.8,  and 48.1  rain  (Fig.  2 a).  The peak 
fractions were pooled, dried,  and rechromatographed  indi- 
vidually on a reversed-phase C4 column.  Fraction P1 sepa- 
rated into three activity peaks with retention times 50.2, 53.3, 
and 55.5 rain (Fig. 2 b). Urea-SDS-PAGE yielded single bands 
with apparent  molecular weights corresponding  to that  of 
II.-8 (Fig. 3). All three preparations were subjected to Edman 
degradation.  No defined sequence could be determined  in 
the material eluting at 50.2 min due to the presence of more 
than one peptide species, while the materials eluting at 53.3 
Figure 3.  Urea-SDS-PAGE  of purified neutrophil-activating peptides. 
Molecular  mass  markers aprotinin (6.5 kD) and lysozyme  (14.4  kD) (lanes 
I and 10), active peptide from pool Pl (49.3-min peak) (lane 2), GROoe 
(lane 3), GKO~, (Lane  4), IL-8 (77 aa) (lane  5), three  preparations of  ENA- 
78 (lanes 6-8), and recombinant IL-8 (lane 9). 
and 55.5 rain could be identified as GROo~ and GRO% respec- 
tively, by sequencing the first  13 NH2-terminal residues (Fig. 
4).  Fraction P2 yielded one single peak with biological ac- 
tivity that could be identified as the 77-amino acid form of 
IL-8 (Fig.  4).  The  72-amino  acid form of IbS,  the major 
product of monocytes, was not detected in the lung epithe- 
lial cell supernatants.  Fraction P3 contained a novel peptide 
with considerable sequence homology to NAP-2 and GKOol, 
but clearly less  homology to  IL-8. 
Structure of ENA-78.  Three  separate preparations  of P3 
were analyzed.  On Urea-SDS-polyacrylamide gels,  they all 
yielded a single band with slightly higher motility than II.-8 
(Fig.  3).  Sequencing  led to  the identification  of 34 NH2- 
terminal and, after acid hydrolysis of the Asp57-Pro58 bond, 
21  COOH-terminal  residues  (Fig.  4).  The  remaining  22 
residues were identified indirectly using PCK methodology. 
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Figure 2.  (a) Separation of neutro- 
phil-sthnulating activities from super- 
natants of Ibid..stimulated A549 cells 
by reversed-phase HPLC on  a  CN- 
propyl column. Three pools  of  activity 
(PI-P3) were collected and  purified 
separately  by reversed-phase  HPLC on 
an analytical C4 column: (b) pool Pl, 
(c) pool P2, (d) pool P3. 
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AGPAAAVLRELRCVCLQTTQGVHPKMISNLQVFA 
DPEAPFLKKVIQKILDGGNKEN 
ASVATELRCQCLQ 
ASVVTELRCQCLQ 
AVLPRSAKELRCQCfKTYSK 
Figure 4.  Amino acid sequences of neutrophil-activating peptides iso- 
lated from A549 cells. Underlined sequences were used for reversed trans- 
lation and construction of sense and antisense primers for the first-strand 
synthesis  and subsequent  PCR. 
The cDNA encoding amino acids 7-78 was amplified using 
sense and antisense  primers and analyzed. PCK with antisense- 
primed cDNA yielded two prominent bands, the lower of 
which had the predicted size of •235  bp (Fig. 5 b).  PCR 
with random hexamer-primed cDNA yielded one single band 
of similar size (Fig. 5 b). The latter fragment was isolated 
from the gel and cloned into plasmid pTZ18R. Five clones 
were sequenced; three contained the correct sequence  between 
the primers, and two were also identical in the primer region 
(Fig.  5 a). 
These results show that ENA-78 consists of 78 amino adds. 
It has a molecular mass of  8,357 daltons and a calculated isoe- 
lectric point of 8.73. The position of the four cysteine  residues 
is identical as in the sequence of I1:8, strongly suggesting 
that ENA-78 belongs  to the CXC family of inflammatory 
peptides. The NH2-terminal sequence up to the first cysteine 
consists of 12 residues  and approximately  corresponds  in length 
to that of the 77-residue form of I1:8 (see Fig. 9). No trun- 
cated variants of either peptide were detected. The sequence 
of ENA-78 contains two potential phosphorylation  sites, one 
for casein kinase II at residue 40 (pqcSkve) and one for pro- 
tein kinase C at residue 47 (vvaSlkn). No apparent sites for 
N-linked glycosylation are present.  Sequence identities be- 
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Figure 6.  Human neutrophil chemotaxis induced by ELISA-78 (~), 
Ib8 (A), and NAP-2 (O).  The response was calculated  as the percent 
neutrophils of input number migrated to the lower side of the polycar- 
bonate membrane.  The results shown here are the mean of three indepen- 
dent experiments. 
tween ENA-78 and NAP-2, GROol, PF-4, Ib8, and yIP-10 
are 53,  52,  44,  22,  and 15%, respectively. 
Biological Activities.  The effects  of ENA-78 on neutrophils 
were studied in comparison with NAP-2 and II:8. As shown 
in Fig. 6, ENA-78 induced a concentration-dependent  migra- 
tion response in vitro between 0.1 and 100 nM. NAP-2 was 
active in the same concentration range and showed a similar 
efficacy.  The percentages of migrating cells at the maximum- 
effective concentration of 100 nM were 22, 15, and 13% for 
IL-8, NAP-2,  and ENA-78, respectively (mean of three ex- 
periments). ENA-78 also induced the release of elastase from 
cytochalasin B-pretreated cells at concentrations ranging be- 
tween 1 and 100 nM, as was the case for NAP-2 and II.-8. 
Figure 5.  (a) Partial amino acid se- 
quence  of ENA-78 as determined by 
oligonucleotide-primed  synthesis  of 
cDNA isolated from A549 cells. Mix- 
tures of degenerated sense primer, en- 
coding amino acids 7-17, and antisense 
primer, encoding amino acids 70-78, 
were used for the PCR. Nucleotide se- 
quences  of  three  individual  cDNAs 
cloned in pTZ18R from the 226-bp band 
(see b). (I) Inosine; (R) A and G; (Y) 
C  and "1~ (D) G, A, and T  (S) A and 
C. (b) Gel electrophoretic analysis  of the 
PCR  products.  Products  of  PCR 
amplifications  were  separated  on  a 
5%  NuSieve  agarose  gel and stained 
with ethidium bromide. Molecular size 
markers (lane 1), control PCR reaction, 
234 bp (lane 2), PCR product obtained 
from A549 cDNA by random hexamer 
priming (lane 3), PCR product obtained 
from A549 eDNA by priming with an- 
risense primer (lane 4),  reaction mix 
without template (lane 5). 
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Figure 7.  Effects of ENA-78 on human neutrophils. 
(a) Release of dastase from cytochalasin B-treated cells 
stimulated with two preparations of ENA-78 (~ and .), 
I1.8 (A), and NAP-2 (O). (b) Rate of cytosolic free cal- 
cium rise in cells stimulated with ENA-78 (~), I1.-8 (A), 
and NAP-2 (O). 
At 100 nM,  I1-8 was consistently two- to threefold more 
effective than NAP-2 and ENA-78 (Fig.  7 a). 
The somewhat lower potency of ENA-78 with respect to 
NAP-2 and I1.8 was also reflected by the measurements of 
stimulus-dependent changes in cytosolic free calcium. As il- 
lustrated in Fig. 7 b, the curve relating the rate of the cal- 
cium rise with the agonist concentration was virtually iden- 
tical  for  II-8  and NAP-2,  and displaced to  the right  for 
ENA-78. Half-maximal rates were reached at ENA-78 con- 
centrations that were -vl0 times higher than those required 
for the reference peptides. 
[Ca2+]i  changes in  response  to  sequential  stimulations 
with I1-8, NAP-2, and ENA-78 were studied to explore the 
possibility  of functional interactions  among these related 
agonists. Desensitization of the neutrophils was always ob- 
served whenever the same agonist was applied twice at the 
same concentration, as reported previously for I1-8 (21, 26). 
The results obtained upon sequential stimulation with com- 
binations of the three agonists are shown in Fig. 8. A first 
stimulation with  100 nM ENA-78 decreased only slightly 
the [Ca2+]i rise induced by the subsequent stimulation with 
100 nM I1-8 or NAP-2.  By contrast, prestimulation with 
100 nM I1.8 or NAP-2 abolished the response to the subse- 
quent challenge with 100 nM ENA-78.  These results sug- 
gest that ENA-78 activates neutrophils via the same or a closely 
related receptor system as I1-8 and analogues. 
Discussion 
A novel neutrophil-activating peptide was identified in the 
conditioned medium of the human type II epithelial cell line 
A549.  The peptide was named ENA-78 to indicate its cel- 
lular origin, its neutrophfl-activating properties, and its total 
number of amino acids. ENA-78 has considerable sequence 
identity with NAP-2 and GROot, and somewhat less with 
II-8. It shares with these peptides and other analogues four 
conserved cysteine residues, therefore, it qualifies  as a new 
member of the CXC family of inflammatory  peptides. ENA-78 
is a potent neutrophil activator with similar biological prop- 
erties as demonstrated for I1-8,  NAP-2, and GROol. It in- 
duces cytosolic free calcium changes, chemotaxis, and exocy- 
tosis  at threshold concentrations ranging between 0.1  and 
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Figure  8.  Cytosolic  free  calcium 
changes in response to sequential stim- 
ulation  of human  neutrophils  with 
combinations  of ENA-78,  Ib8,  and 
NAP-2 at 100 nM. 
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Figure 9.  Amino acid sequences of 
ENA-78 and related peptides aligned ac- 
cording  their  four  cysteine  residues 
(bold). For GROB  and GRO3',  only 
amino acids that differ from GROo~ are 
shown. 
3 nM. Crossdesensitization studies indicate that ENA-78, Ib8, 
and NAP-~. act  on neutrophils via  the same  or  a related 
receptors. 
During the last few years, a superfamily of 8-10-kD inflam- 
matory cytokines with four characteristic  cysteine residues 
has been recognized. On the basis of the arrangement of the 
first two cysteines, which can be adjacent (CC) or separated 
by one amino acid (CXC),  and the chromosomal location 
of their genes, two subfamilies can be distinguished. The CC 
subfamily includes,  among other peptides,  the monocyte 
chemotactic protein 1 (MCP-1), nANTES, and 1-309, which 
were shown to be chemotactic for monocytes (27). In addi- 
tion, nANTES was reported to attract certain populations 
of lymphocytes (28). No member of the CC subfamily has 
been reported to stimulate neutrophils. Two murine homo- 
logues, however, MIP-lot and MIP-1/~, have been shown to 
induce neutrophil infiltration in vivo (29,  30).  As already 
pointed out, the newly discovered peptide ENA-78 belongs 
to the CXC subfamily, which includes Ib8, NAP-2, and three 
forms of GRO  (31) (Fig.  9).  It was recently shown that 
GROol, GROB, and GROy are encoded by related, but dis- 
tinct genes (32), and that GtLO~ and GRO3' are the human 
homologues of the murine inflammatory proteins MIP-2~/ 
and MIP-2ot,  respectively  (33). 
The present study revealed an unusual versatility of A549 
cells that produced, in addition to ENA-78, the 77-amino 
acid form of IL-8 as well as GROot, GRO3',  and a minor 
unidentified peptide, which on the basis of its HPLC elution 
profile and physicochemical properties appears to be closely 
related to GRO/~ (MIP-2o~). Unstimulated A549 cells con- 
stitutively released small amounts of ENA-78 and IbS. The 
release of these factors was not increased by LPS stimulation. 
However, Ibl~ and TNF-c~, two proinflammatory cytokines 
that induce the production of I1-8 in a variety of cells (4), 
led to a massive release of ENA-78, the GRO peptides, and 
IL-8 in A549 cells. Stimulus dependency is in agreement with 
recent observations by Standiford et al.  (18) that the levels 
of II:8 mRNA in A549 cells are low in the absence of stimu- 
lation or in the presence of LPS, and high upon exposure 
to IL-1B or TNF-ol.  IL-8 was recovered exclusively as the 
77-amino acid form, which is obtained in minor amounts 
in monocyte cultures (34), and was the most abundant variant 
in cultures of endothdial cells stimulated with IL-1/~ (35). 
By analogy to  the  77-72-amino  acid  truncation of Ib8, 
resulting  in  enhanced  activity,  it  is  possible  that  NH2- 
terminal processing of ENA-78 is also required for maximum 
activity. 
Several acute and chronic lung disorders are characterized 
by the presence of high numbers of neutrophils. Enhanced 
chemotactic activity for neutrophils has been observed in the 
bronchoalveolar lavage fluids of patients with adult respira- 
tory distress syndrome (36),  idiopathic pulmonary fibrosis 
(15), and asbestosis (37). Elevated levels of elastase were ob- 
served as well, indicating the presence of activated  neutro- 
phils (38). Up to now, I1.,8 was the only peptide to be con- 
sidered as mediator of neutrophil recruitment in the lung 
(16-18). The present experiments demonstrate the potential 
involvement of several IL-8 analogues.  Since A549 cells have 
retained distinguishing properties of type II alveolar epithe- 
lial cells, such as the characteristic  multilamellar inclusion 
bodies and the capacity to produce surfactant (39), it must 
be assumed that the concomitant production of several mem- 
bers of the I1.-8 family of peptides may also occur in vivo 
within the alveolar space. Epithelial cells, which also pro- 
duce monocyte chemotactic peptide 1 (40), may thus func- 
tion as second-stage producers of leukocyte attractants in re- 
sponse to proinflammatory cytokines released from alveolar 
macrophages. Such a multipotency possibly denotes an im- 
portant role in directing neutrophils and monocytes to the 
alveolus during inflammatory states. 
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